EGFR and non-small cell lung carcinoma: In a separate meta-analysis that included 1283 patients with resected EGFR-mutant NSCLC, it was found that the risk of CNS recurrence in those who received osimertinib was significantly lower (odds ratio of 0.11, 95% CI 0.04-0.32) compared to those who received gefitinib or erlotinib (odds ratio of 0.95, 95% CI 0.36-2.49) [23].